Semaglutide, a glucagon-like peptide-1 receptor agonist, may be associated with increased risk of a rare eye condition, results from a large-scale retrospective study have suggested. Following anecdotal experience that the weight loss drug may be linked to non-arteritic anterior ischemic optic neuropathy (NAION), researchers in the United States analysed data over six years from more … Continue reading Semaglutide linked to sight-threatening eye condition, study results suggest